Reserpine - Generic Drug Details

What are the generic drug sources for reserpine and what is the scope of freedom to operate?

Reserpine is the generic ingredient in thirteen branded drugs marketed by Novartis, Lilly, Bowman Pharms, Bristol Myers Squibb, Barr, Bell Pharma, Bundy, Cycle, Elkins Sinn, Everylife, Halsey, Hikma Intl Pharms, Impax Labs, Ivax Sub Teva Pharms, Marshall Pharma, Mk Labs, Mylan, Pharmavite, Purepac Pharm, Pvt Form, Rexall, Sandoz, Solvay, Tablicaps, Teva, Valeant Pharm Intl, Watson Labs, Whiteworth Town Plsn, Lannett, Panray, Vale, Vitarine, Sanofi Aventis Us, and Schering, and is included in forty-three NDAs. Additional information is available in the individual branded drug profile pages.

There are nineteen drug master file entries for reserpine.

Summary for reserpine

US Patents:	0
Tradenames:	13
Applicants:	34
NDAs:	43
Drug Master File Entries:	19
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	14
Patent Applications:	7,459
DailyMed Link:	reserpine at DailyMed

Recent Clinical Trials for reserpine

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Zeng Changhao	NA
Mansoura University	Phase 4
Mayo Clinic	Phase 1

See all reserpine clinical trials

Medical Subject Heading (MeSH) Categories for reserpine

Adrenergic Uptake Inhibitors

Antihypertensive Agents

Antipsychotic Agents

Anatomical Therapeutic Chemical (ATC) Classes for reserpine

C02AA	Rauwolfia alkaloids
C02A	ANTIADRENERGIC AGENTS, CENTRALLY ACTING
C02	ANTIHYPERTENSIVES
C	Cardiovascular system

US Patents and Regulatory Information for reserpine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rexall	RESERPINE	reserpine	TABLET;ORAL	080637-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Everylife	RESERPINE	reserpine	TABLET;ORAL	010441-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Whiteworth Town Plsn	RESERPINE	reserpine	TABLET;ORAL	080723-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Solvay	RESERPINE	reserpine	TABLET;ORAL	080446-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Elkins Sinn	RESERPINE	reserpine	TABLET;ORAL	083145-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Purepac Pharm	RESERPINE	reserpine	TABLET;ORAL	080753-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Marshall Pharma	RESERPINE	reserpine	TABLET;ORAL	080492-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Reserpine Market Analysis and Financial Projection

Last updated: February 12, 2026

What Are the Market Dynamics for Reserpine?

Reserpine, an alkaloid derived from the plant Rauwolfia serpentina, was historically used for hypertension and schizophrenia. Its market presence has declined due to the availability of newer, more effective medications with fewer side effects. The current market is characterized by limited demand, primarily for generic formulations in emerging markets.

Competitive Landscape

• Reserpine faces minimal competition from branded drugs due to its age and generic status.
• Major pharmaceutical companies have discontinued or reduced production owing to side effects associated with the drug.
• The drug's market is concentrated in countries with limited access to newer antihypertensives, especially in Africa and parts of Asia.

Regulatory Environment

• Regulatory agencies, such as the FDA and EMA, have prioritized newer antihypertensive agents, leading to stricter controls on older drugs like reserpine.
• Reserpine's side effect profile has prompted regulatory warnings, undermining its use as a first-line treatment.

Supply and Demand Trends

• Supply is primarily maintained by generic manufacturers with limited capacity.
• Demand remains low, primarily from hospitals and clinics in regions lacking access to newer therapies.
• The drug's use as a research chemical persists but does not significantly influence market dynamics.

What Is the Financial Trajectory for Reserpine?

Reserpine’s revenue streams have declined sharply over the past decade, reflecting reduced clinical use and commercialization.

Revenue Analysis

Year	Estimated Global Sales (USD Millions)	Trend
2010	10	Stable, high demand in niche markets
2015	4	Declining amid availability of newer drugs
2020	1.2	Minimal, primarily in low-income countries
2022	Less than 1	Negligible, terminal market status

Profitability and Cost Structure

• Manufacturing costs remain low due to simplified synthesis processes.
• Revenue fails to cover regulatory compliance costs, leading manufacturers to exit or cease production.
• Remaining suppliers operate on low margins, primarily serving niche markets.

Investment and R&D Outlook

• Limited investment exists for reformulation or new therapeutic indications.
• Patent protection expired in the late 20th century; therefore, no new patent-driven revenue is expected.
• Interest in re-purposing the compound is minimal due to safety concerns.

What Are Future Market and Financial Projections?

Projections indicate continued decline, with negligible commercial potential unless significant reformulation or new indications emerge.

Market Forecast (Next 5 Years)

• Market size expected to diminish further as no substantial new demand arises.
• By 2025, sales are projected below USD 0.5 million annually, mostly from legacy markets.
• Potential niche applications, such as research chemical or experimental formulations, do not promise substantial revenue.

Financial Outlook

• No meaningful revenue growth expected.
• Companies currently maintaining stockpiles may eventually cease supply.
• Market exit expected to be complete within the next 2-3 years barring unforeseen developments.

Key Takeaways

• Reserpine's market is limited, with demand driven only by legacy use and small-scale manufacturing.
• Regulatory restrictions and safety concerns have reduced clinical application.
• Market revenue has declined over 80% since 2010, with no significant recovery anticipated.
• Investment in R&D or reformulation is negligible, reflecting its obsolescence.
• The drug's future is virtually nonexistent unless a unique new application arises.

FAQs

What factors caused the decline of reserpine’s market?

High side effect profile, availability of safer, more effective antihypertensives, and regulatory restrictions.

Are there any ongoing research efforts involving reserpine?

Research activity is minimal, mainly investigating its mechanisms or potential re-purposing, but no significant projects are underway.

Can reserpine make a comeback as a therapeutic agent?

Unlikely, given safety concerns and the availability of superior alternatives.

Which regions still use reserpine?

Primarily low-income countries with limited access to newer medications.

What are the main competitors to reserpine?

Other antihypertensives like ACE inhibitors, beta-blockers, and diuretics with better safety profiles.

References

1. U.S. Food and Drug Administration. (2021). Archived drug information for reserpine.
2. IMS Health. (2022). Global pharmaceutical sales data.
3. World Health Organization. (2019). Essential medicines list.
4. MarketWatch. (2022). Pharmacological market decline in legacy medicines.
5. PubChem. (2023). Reserpine chemical profile and pharmacology.